Market Research Future (MRFR) has published a cooked research report on the “Global Keratoconus Treatment Market” that contains the information from 2023 to 2032.
The keratoconus treatment market is expected to register a CAGR of 3.70% during the forecast period and is expected to hit USD 0.41 Billion by 2032.
MRFR recognizes the following companies as the
key players in the global keratoconus treatment market—HOYA Vision Care Company (Japan), Menicon Co., Ltd. (Japan), Cooper Companies, Inc. (US), Bausch Health (Canada), SynergEyes (US), Carl Zeiss Meditec AG (Germany), Contamac (UK), SEED Co., Ltd (Japan), Novartis AG (Switzerland), and Johnson & Johnson Services, Inc (US).Market Highlights
Keratoconus is a progressive eye condition in which the cornea, usually round and small, appears cone-like. Keratoconus frequently has to do with light overexposure, constant eye rubbing, improperly fitting contact lenses and chronic eye irritation. Keratoconus care depends on the seriousness of the disease and how easily the condition progresses.
The global keratoconus treatment market is mainly driven by the increasing incidence of keratoconus disorders, increasing ultraviolet and sun exposure and favorable government funding research and prevention programs of ophthalmic disorders. According to the American Journal of Ophthalmology, around 50-200 of every 100,000 people are afflicted with keratoconus. In addition, ultraviolet is regarded as one of the main causes for the development of keratoconus because of its oxidative damage. Thus, a higher prevalence of keratoconus has been identified in Saudi Arabia, Iran, New Zealand, Israel, and some Pacific Islands due to the high ultraviolet exposure.However, lack of awareness and side effects of keratoconus treatment are expected to hamper the growth of the market during the forecast period.
Segment Analysis
The global keratoconus treatment market has been divided based on keratoconus type, treatment type, and end user.
The market, based on keratoconus type, has been segregated into corneal hydrops, forme fruste keratoconus, posterior keratoconus, keratoglobus, pellucid marginal degeneration, and others.
On the basis of treatment type, the market is bifurcated into lenses, surgery, corneal cross-linking, and others. On the basis of lens type, it can further sub-segmented into soft contact lenses, gas permeable contact lenses, scleral and semi-scleral lenses, piggybacking contact lenses, hybrid contact lenses, prosthetic lenses, and others. Based on surgery type, it can be further sub-segmented into corneal transplant, Intacs, and others.
On the basis of end user, the market is bifurcated into eye clinics, hospitals, and others.
Regional Analysis
The global keratoconus treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa. The Americas is expected to command the largest market share due to a well-developed healthcare sectorand ongoing technological advancements in the US. According to the American Journal of Ophthalmology, around 50-200 of every 100,000 people are afflicted with keratoconus.Additionally, a high number of cataract surgeries and thegrowing mergers & acquisitions and product launches in this regionare also contribute to market growth. Europe held a substantial share in the global keratoconus treatment market. This can be attributed to the increasing support from the government, the well-establishedmedical industry in the region and the growing cases of keratoconus.Asia-Pacific is estimated to be the fastest-growing region in the global market owing to the high merger and acquisition activities and product approvals in the region.The keratoconus treatment market in Middle East & Africa is expected to witness steady growth during the review period. In the Middle East, the adoption rate of newer diagnostic instruments was high in countries such as South Africa, the UAE, and Saudi Arabia.
Key Findings of the Study
- The global keratoconus treatment market was valued at USD 55 millionin 2019 and is expected to register a CAGR of 4.72% during the assessment period
- The Americas accounted for the largest share of the global market due to the well-developed healthcare sector, well-developed medical facilities, and ongoing technological advancements.
- Based on keratoconus type, the corneal hydrops segment accounted for the largest market share of 26.7% in 2019.
- Based on treatment type, the corneal cross-linking segment is expected to register the highest CAGR of 5.04% during the forecast period.
- Based on the end user, the eye clinics segment accounted for the largest market share with a value of USD 208.97 million in 2019
Some of the players operating in the keratoconus treatment market are HOYA Vision Care Company, Bausch Health, Carl Zeiss Meditec AG, and Novartis AG.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Keratoconus Treatment Market Research Report
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Companies Covered | 15 |
Pages | 153 |
Certified Global Research Member
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.